Informations générales (source: ClinicalTrials.gov)

NCT06048510 En recrutement
New Markers of Glycation to Predict Gestational Diabetes Mellitus and Macrosomia. (GLYCAGEST)
Interventional
  • Diabète
  • Macrosomie foetale
  • Grossesse chez les diabétiques
  • Diabète gestationnel
N/A
University Hospital, Bordeaux (Voir sur ClinicalTrials)
décembre 2023
avril 2025
29 juin 2024
Gestational diabetes mellitus (GDM) increases the risk of macrosomia and other adverse pregnancy outcomes. Screening strategies are debated: universal vs. selective, and macrosomia may begin before the time of screening, suggesting that glycation markers may have an interest. The objective of this trail is to compare novel markers: skin autofluorescence and glycated albumin, to HbA1c (reference) as predictors of GDM, macrosomia and other adverse outcomes, in pregnant women.
 Voir le détail

Etablissements

Les établissements sans correspondance certaine dans le répertoire FINESS dont les données sont issues de ClinicalTrials.gov Origine et niveau de fiabilité des données
Hopital Pellegrin - 33000 - Bordeaux - France FOUSSARD NINON, Dr En recrutement Contact (sur clinicalTrials)

Critères

Tous
Inclusion criteria:

1. Age ≥ 18 years

2. Singleton pregnancy (or twin pregnancy reduced spontaneously or medically before 14
weeks of amenorrhea)

3. Gestational age at inclusion <28 weeks of amenorrhea

4. Participant affiliated with or beneficiary of a social security scheme

5. Collection of patient consent.


1. Gestational age at inclusion ≥ 28 weeks of amenorrhea

2. Multiple pregnancy

3. Known diabetes prior to pregnancy

4. History of bariatric surgery

5. Expected delivery in another maternity unit not participating in the study

6. Person deprived of liberty by judicial or administrative decision

7. Guardianship or curatorship

8. Participant not affiliated or not benefiting from a social security scheme.